166 related articles for article (PubMed ID: 1446856)
1. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.
De Vos M; Verdievel H; Schoonjans R; Praet M; Bogaert M; Barbier F
Gut; 1992 Oct; 33(10):1338-42. PubMed ID: 1446856
[TBL] [Abstract][Full Text] [Related]
2. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
4. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
[TBL] [Abstract][Full Text] [Related]
5. Oroileal transit of slow release 5-aminosalicylic acid.
Goebell H; Klotz U; Nehlsen B; Layer P
Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
7. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
9. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
[TBL] [Abstract][Full Text] [Related]
10. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
[TBL] [Abstract][Full Text] [Related]
11. Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration.
Schoonjans R; De Vos M; Schelfhout AM; Praet M; Elewaut A
Dis Colon Rectum; 1996 Jul; 39(7):788-93. PubMed ID: 8674372
[TBL] [Abstract][Full Text] [Related]
12. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
Gionchetti P; Campieri M; Venturi A; Rizzello F; Ferretti M; Brignola C; Miglioli M
Aliment Pharmacol Ther; 1996 Aug; 10(4):601-5. PubMed ID: 8853765
[TBL] [Abstract][Full Text] [Related]
13. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
14. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
[TBL] [Abstract][Full Text] [Related]
15. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
16. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol Suppl; 1988; 148():54-9. PubMed ID: 2906478
[TBL] [Abstract][Full Text] [Related]
17. Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses.
Knoll U; Strauhs P; Schusser G; Ungemach FR
J Vet Pharmacol Ther; 2002 Apr; 25(2):135-43. PubMed ID: 12000534
[TBL] [Abstract][Full Text] [Related]
18. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
[TBL] [Abstract][Full Text] [Related]
19. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
20. Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption.
Wiltink EH; Mulder CJ; Stolk LM; Rietbroek R; Verbeek C; Tytgat GN
Scand J Gastroenterol; 1990 Jun; 25(6):579-84. PubMed ID: 2359989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
